

Short report on DRIVE-AB Stakeholder Meeting: Towards a global definition of responsible antibiotic use

On Wednesday 28th of September the Work Package 1A team, “Responsible use of antibiotics, new and old” held a web-conference meeting titled, ‘Towards a global definition of **responsible** antibiotic use’. This meeting was the last step of the international and multidisciplinary consensus procedure towards a global definition of **responsible** antibiotic use, one of the team’s main objectives.

DRIVE-AB partners presented the methodology and the results of the survey towards a global definition of **responsible** antibiotic use. In this survey, stakeholders and experts were asked to appraise the relevance of several domains for defining **responsible** antibiotic use. Meeting participants were selected based on participation in the survey, their expertise, experience, position and country. Domains of responsible antibiotic use for which there was disagreement, newly proposed domains and proposals of rephrasing of domains were discussed during the two-hour meeting.

The results of the international and multidisciplinary consensus procedure towards a global definition of “responsible antibiotic use” will be reported in the Innovative Medicines Initiative, included in the final DRIVE-AB report and described in a manuscript for publication in 2017.

Meeting participants:

Stakeholder Group	Participants
Chair/Moderator	Jeroen Schouten Radboud University Medical Center, the Netherlands
Medical Community	Marc Mendelson Head, Division of Infectious Diseases & HIV Medicine, Department of Medicine University of Cape Town, South-Africa Franky Buyle Hospital pharmacist, Ghent University Hospital, Belgium Karin Thursky Director NHMRC National Centre for Antimicrobial Stewardship, Royal Melbourne Hospital, Australia
Patients/Global Public Health	Marie-Paule Kieny Assistant Director-General - Health Systems and Innovation, World Health Organization, Switzerland Rupa Kanapathipillai Infectious Disease Advisor, Médecins Sans Frontières, US Sujith John Chandy Professor, Clinical Pharmacology, Pushpagiri Medical College Hospital, India & Department of Public Health Sciences, Karolinska Institutet, Sweden
Pharma – SMEs, R&D	John Rex , Senior Vice President and Chief Strategy Officer, AstraZeneca, US
Payers/ Policy makers/ Government/ Regulators	Arjun Srinivasan Associate Director for Healthcare Associated Infection Prevention Programs, Centers for Disease Control and prevention (CDC), US Diamantis Plachouras Expert Antimicrobial Resistance and Healthcare-associated Infections, European Centre for Disease Prevention and Control (ECDC), Sweden Charles Penn Advisor Global Health Security, Department of Health, UK
DRIVE-AB Work Package 1A	Inge Gyssens Radboud University Medical Center, the Netherlands Annelie Monnier Radboud University Medical Center, the Netherlands